ECSP11011420A - Procedimientos para mejorar la farmacocinética - Google Patents

Procedimientos para mejorar la farmacocinética

Info

Publication number
ECSP11011420A
ECSP11011420A EC2011011420A ECSP11011420A ECSP11011420A EC SP11011420 A ECSP11011420 A EC SP11011420A EC 2011011420 A EC2011011420 A EC 2011011420A EC SP11011420 A ECSP11011420 A EC SP11011420A EC SP11011420 A ECSP11011420 A EC SP11011420A
Authority
EC
Ecuador
Prior art keywords
pharmacocinetics
procedures
improve
cytochrome
raise
Prior art date
Application number
EC2011011420A
Other languages
English (en)
Inventor
Jonathan Q Tran
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP11011420A publication Critical patent/ECSP11011420A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

El objeto de la presente invención, es el de elevar los niveles en sangre de un compuesto de la fórmula I, mediante la co-administración con un inhibidor del citocromo P450.
EC2011011420A 2009-04-25 2011-10-25 Procedimientos para mejorar la farmacocinética ECSP11011420A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17272209P 2009-04-25 2009-04-25

Publications (1)

Publication Number Publication Date
ECSP11011420A true ECSP11011420A (es) 2011-11-30

Family

ID=42236685

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011420A ECSP11011420A (es) 2009-04-25 2011-10-25 Procedimientos para mejorar la farmacocinética

Country Status (36)

Country Link
US (4) US20100272682A1 (es)
EP (1) EP2421527B1 (es)
JP (1) JP5523552B2 (es)
KR (1) KR101471238B1 (es)
CN (2) CN102413827A (es)
AR (1) AR076388A1 (es)
AU (1) AU2010240893B2 (es)
BR (1) BRPI1015147B1 (es)
CA (1) CA2758644C (es)
CL (1) CL2011002643A1 (es)
CO (1) CO6440593A2 (es)
CR (1) CR20110551A (es)
DK (1) DK2421527T3 (es)
EC (1) ECSP11011420A (es)
ES (1) ES2683736T3 (es)
HK (1) HK1215858A1 (es)
HR (1) HRP20181306T1 (es)
HU (1) HUE040182T2 (es)
IL (1) IL215620A (es)
LT (1) LT2421527T (es)
MA (1) MA33212B1 (es)
MX (2) MX2011011105A (es)
MY (1) MY169734A (es)
NZ (1) NZ595917A (es)
PE (1) PE20120638A1 (es)
PL (1) PL2421527T3 (es)
PT (1) PT2421527T (es)
RS (1) RS57501B1 (es)
RU (1) RU2591830C2 (es)
SG (1) SG175328A1 (es)
SI (1) SI2421527T1 (es)
TR (1) TR201809600T4 (es)
TW (1) TWI468160B (es)
UA (1) UA103801C2 (es)
WO (1) WO2010122087A1 (es)
ZA (1) ZA201107421B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045266A1 (en) * 2008-10-15 2010-04-22 Intermune, Inc. Therapeutic antiviral peptides
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
EP2802595B1 (en) 2012-01-11 2016-01-06 AbbVie Inc. Processes for making hcv protease inhibitors
MX2014015942A (es) * 2012-06-27 2015-07-17 Abbvie Inc Tratamiento de combinacion con abt-450 y ritonavir y e. g. abt-072 y/o abt-333 para utilizarse en el tratamiento del vhc.
BR112015007887A2 (pt) 2012-10-08 2017-07-04 Abbvie Inc compostos úteis para produzir inibidores hcv protease
PL3137078T3 (pl) * 2014-05-01 2019-08-30 Eiger Biopharmaceuticals, Inc. Leczenie zakażenia wirusem zapalenia wątroby typu delta
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
HUE054068T2 (hu) 2015-04-21 2021-08-30 Eiger Biopharmaceuticals Inc Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69334250D1 (de) 1992-12-29 2009-01-29 Abbott Lab Verfahren und Intermediate zur Herstellung von retroviralen Proteasehemmern
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
IL141438A0 (en) 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
SK742003A3 (en) * 2000-07-21 2003-06-03 Schering Corp Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
KR20050085681A (ko) 2002-12-16 2005-08-29 베링거 인겔하임 인터내셔날 게엠베하 프로테아제 억제제와 같은 사이토크롬 ｐ450의 억제제와함께 비-뉴클레오시드 역전사효소 억제제(ｎｎｒｔｉ)를함유하는 배합물의 용도
CN1893978A (zh) * 2003-10-27 2007-01-10 沃泰克斯药物股份有限公司 用于hcv治疗的组合
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
US20120220520A1 (en) * 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment

Also Published As

Publication number Publication date
CR20110551A (es) 2011-12-13
BRPI1015147B1 (pt) 2022-03-08
US20180318267A1 (en) 2018-11-08
AU2010240893A1 (en) 2011-11-03
RU2011142651A (ru) 2013-05-27
HUE040182T2 (hu) 2019-02-28
KR101471238B1 (ko) 2014-12-12
MX351185B (es) 2017-10-04
WO2010122087A1 (en) 2010-10-28
NZ595917A (en) 2014-02-28
UA103801C2 (ru) 2013-11-25
JP2012524753A (ja) 2012-10-18
CA2758644A1 (en) 2010-10-28
CL2011002643A1 (es) 2012-05-25
MA33212B1 (fr) 2012-04-02
AR076388A1 (es) 2011-06-08
PL2421527T3 (pl) 2018-10-31
DK2421527T3 (en) 2018-08-13
SI2421527T1 (sl) 2018-09-28
US20170119739A1 (en) 2017-05-04
US20200230112A1 (en) 2020-07-23
PE20120638A1 (es) 2012-05-26
IL215620A0 (en) 2012-01-31
KR20120014170A (ko) 2012-02-16
TR201809600T4 (tr) 2018-07-23
HK1215858A1 (zh) 2016-09-23
HRP20181306T1 (hr) 2018-10-19
SG175328A1 (en) 2011-11-28
US10918626B2 (en) 2021-02-16
PT2421527T (pt) 2018-08-02
BRPI1015147A2 (pt) 2018-01-30
MY169734A (en) 2019-05-14
CN105233249A (zh) 2016-01-13
EP2421527A1 (en) 2012-02-29
EP2421527B1 (en) 2018-06-13
CO6440593A2 (es) 2012-05-15
RS57501B1 (sr) 2018-10-31
LT2421527T (lt) 2018-09-10
CN102413827A (zh) 2012-04-11
US20100272682A1 (en) 2010-10-28
TWI468160B (zh) 2015-01-11
RU2591830C2 (ru) 2016-07-20
MX2011011105A (es) 2011-11-18
TW201041582A (en) 2010-12-01
JP5523552B2 (ja) 2014-06-18
ZA201107421B (en) 2022-11-30
CA2758644C (en) 2018-01-09
ES2683736T3 (es) 2018-09-27
IL215620A (en) 2015-10-29
AU2010240893B2 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
CR20110551A (es) Procedimientos para mejorar la farmocinética
ECSP12011573A (es) Compuestos tetracíclicos
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
EA201290800A1 (ru) Гетероциклическое соединение
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
MX391175B (es) Macrociclos peptidomimeticos.
ECSP13013074A (es) Nuevos derivados de piridina
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
CR20130539A (es) Triazolopiridinas
GT201200230A (es) Inhibidores del virus de la hepatitis c
GT201400195A (es) Compuestos de heterociclilo como inhibidores de mek
CR20120297A (es) Espironucleósidos uracílicos oxetánicos
CR20120295A (es) Triazolopiridinas
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
CR20110046A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
CR20150250A (es) Nuevos derivados de piridina
CR20120637A (es) Triazolopiridinas sustituidas
UY32481A (es) Derivados de benzofurano
CR20140535A (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
CR20150084A (es) 2-oxo-2,3-dihidro-indoles
CR20130597A (es) Isoxazolinas como agentes terapèuticos